This article was originally published in The Rose Sheet
Executive SummaryGerman company lowers FY 2004 organic growth forecast from 3%-4% to 2% due to "ongoing sluggish demand" in Europe and a "stagnant to downward trend of the markets and tougher competition as well as pricing activities" of the firm's competitors. Brand investment and cost reduction measures already have been instituted to improve Henkel's performance, company adds. Firm will report second quarter results Aug. 9...
You may also be interested in...
What will the fall-out of political tensions between the EU and Switzerland mean for notified bodies based in Switzerland, and for the future recognition of CE marks granted in one of the most important medtech markets in Europe?
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.